David Miller, MD
Gynecologic Oncology · Dallas, TXNPI 1568429934
Payments from drug & device makers
Across 667 payments — averaging $2960.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.2M
- Karyopharm Therapeutics Inc.$328K
- Pfizer$114K
- Incyte Corporation$91K
- GSK$59K
- Ascendis Pharma Endocrinology Inc$42K
- plus $161K from 26 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$150
What the payments were for
- Consulting fees$78,04477%
- Speaking & faculty fees$5,5455%
- Travel & lodging$6,3966%
- Food & beverage$10,94811%
- Education$5040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 237 | $1,180,494 |
| Karyopharm Therapeutics Inc. | 79 | $327,860 |
| Pfizer | 10 | $113,633 |
| Incyte Corporation | 118 | $91,353 |
| GSK | 47 | $58,781 |
| Ascendis Pharma Endocrinology Inc | 1 | $41,513 |
| EMD Serono, Inc. | 9 | $34,118 |
| Tesaro, Inc. | 49 | $27,008 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $22,132 |
| Bayer | 3 | $18,900 |
| Baxter Healthcare | 1 | $15,531 |
| Eisai Inc. | 20 | $12,217 |
| AstraZeneca | 22 | $8,519 |
| Eisai CO., LTD. | 2 | $5,775 |
| Myriad Genetic Laboratories, Inc. | 5 | $3,275 |
| Aadi Bioscience, Inc. | 2 | $2,709 |
| Novartis | 1 | $2,167 |
| Boston Scientific | 2 | $1,612 |
| Stryker | 3 | $1,353 |
| Genmab U.S., Inc. | 11 | $888 |
| Clovis Oncology, Inc. | 12 | $822 |
| AbbVie | 3 | $771 |
| Merck Kgaa | 1 | $690 |
| Seagen Inc. | 5 | $490 |
| Biom'up France SAS | 4 | $441 |
| Genentech USA, Inc. | 5 | $434 |
| Medical Device Business Services, Inc. | 1 | $325 |
| Immunogen, Inc. | 2 | $226 |
| Novocure Inc. | 1 | $128 |
| Pacira Pharmaceuticals Incorporated | 1 | $101 |
| Galvanize Therapeutics, Inc | 1 | $34 |
| Tanabe Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$21,863
- ZEJULA$17,032
- JEMPERLI$14,912
- LYNPARZA$5,171
- myChoice CDx$3,150
- KEYTRUDA$2,389
- KISQALI$2,167
- XPOVIO$1,317
- SPY-PHI SYSTEM$712
- TIVDAK$660
- 1588 HD 3 CHIP CAMERA$641
- Rubraca$627
- HemoBlast Bellows$419
- Elahere$342
- Avastin$272
- Enhertu$121
- myRisk$113
- CLINICAL TRIAL PRODUCT$112
- EXPAREL$101
How this compares
$1,974,318 in reported general payments places this provider in the 90th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $9,013 |
| Megestrol Acetate | 11 | $1,162 |
| Estradiol | 16 | $1,158 |
| Dexamethasone | 17 | $402 |
| Oxycodone Hcl | 21 | $401 |
| Letrozole | 12 | $206 |
| Ondansetron Hcl | 17 | $169 |
| Prochlorperazine Maleate | 19 | $164 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Dallas
- Jayanthi LeaDallas$3.9M
- Dustin MandersDallas$171K
- Brandon SawyerDallas$131K
- Thomas HeffernanDallas$95K
- Laura DivineDallas$75K
- Jonathan OhDallas$7K
- Jessica GillenDallas$6K
- Pamela SolimanHouston$30.7M
- Noelle ClovenFort Worth$7.3M
- Christine LeeShenandoah$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.